| 1. |
- Buendia, Ruben, 1982, et al.
(författare)
-
Estimation of Arm Adipose Tissue Quotient Using Segmental Bioimpedance Spectroscopy
- 2018
-
Ingår i: Lymphatic Research and Biology. - : Mary Ann Liebert Inc. - 1557-8585 .- 1539-6851. ; 16:4, s. 377-384
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Breast cancer-related lymphedema (BCRL) is a chronic condition characterized by accumulation of lymph fluid that may subsequently become fibrotic with infiltration of adipose tissue. Bioimpedance spectroscopy (BIS) is the preferred method for early detection of lymphedema as it can estimate extracellular lymph fluid. This study developed a modified impedance technique that concurrently estimates both lymph accumulation and increases in adipose tissue. Methods and Results: BIS was used to estimate the adipose tissue volume in a cohort of healthy women (n=171), which was found to be highly correlated (r>0.87) with measurements of adipose tissue obtained using the reference method of dual-energy X-ray absorptiometry (DXA). In a separate cohort of women with BCRL (n=16), adipose volumes measured by BIS and reference method, respectively, were 2452.9933.3mL and 2109.1 +/- 824 6mL for affected arms; 1770.9 +/- 747.8mL and 1801.4 +/- 775.7mL for unaffected arms; and comparable values for a group of age-matched controls were 1862.5 +/- 661.6mL and 1657.0 +/- 641.1mL for age-matched control arms. The increase in adipose tissue in affected arms was significant irrespective of the method of measurement, p<0.02 and p<0.001 for BIS and DXA, respectively. Conclusions: An impedance method is described that can estimate increase both in lymph accumulation and adipose tissue in breast cancer-related lymphedema.
|
|
| 2. |
- Currow, David, et al.
(författare)
-
A pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-Arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness : Breathlessness, Exertion and Morphine Sulfate (BEAMS) study protocol
- 2017
-
Ingår i: BMJ Open. - : BMJ. - 2044-6055. ; 7:7
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction Chronic breathlessness is highly prevalent and distressing to patients and families. No medication is registered for its symptomatic reduction. The strongest evidence is for regular, low-dose, extended-release (ER) oral morphine. A recent large phase III study suggests the subgroup most likely to benefit have chronic obstructive pulmonary disease (COPD) and modified Medical Research Council breathlessness scores of 3 or 4. This protocol is for an adequately powered, parallel-Arm, placebo-controlled, multisite, factorial, block-randomised study evaluating regular ER morphine for chronic breathlessness in people with COPD. Methods and analysis The primary question is what effect regular ER morphine has on worst breathlessness, measured daily on a 0-10 numerical rating scale. Uniquely, the coprimary outcome will use a FitBit to measure habitual physical activity. Secondary questions include safety and, whether upward titration after initial benefit delivers greater net symptom reduction. Substudies include longitudinal driving simulation, sleep, caregiver, health economic and pharmacogenetic studies. Seventeen centres will recruit 171 participants from respiratory and palliative care. The study has five phases including three randomisation phases to increasing doses of ER morphine. All participants will receive placebo or active laxatives as appropriate. Appropriate statistical analysis of primary and secondary outcomes will be used. Ethics and dissemination Ethics approval has been obtained. Results of the study will be submitted for publication in peer-reviewed journals, findings presented at relevant conferences and potentially used to inform registration of ER morphine for chronic breathlessness. Trial registration number NCT02720822; Pre-results.
|
|
